Tomocube, Inc., a prominent player in the health care sector, has been making significant strides in the field of optical devices and medical equipment. Headquartered in Daejeon, South Korea, the company has established itself as a leader in the development and sale of advanced imaging technologies. As of November 8, 2026, Tomocube’s stock closed at 25,500 KRW on the Korea Exchange KOSDAQ, reflecting a market capitalization of approximately 341.27 trillion KRW. Despite a challenging year, with the stock reaching a 52-week low of 23,300 KRW on November 5, 2026, the company’s innovative product offerings continue to drive its market presence.
Tomocube’s flagship products, the HT-X1 and HT-2H, are at the forefront of holotomography (HT) technology, providing unparalleled capabilities in live-cell imaging and analysis. The HT-X1 is renowned for its precision in live-cell imaging, making it an indispensable tool for researchers and medical professionals seeking to observe cellular processes in real-time. Meanwhile, the HT-2H extends these capabilities into three-dimensional imaging, offering a comprehensive view of cellular structures and dynamics.
Complementing these hardware solutions, Tomocube offers TomoAnalysis, a sophisticated 3D image visualization and analysis software. This software enhances the utility of Tomocube’s imaging devices by enabling detailed analysis and interpretation of complex biological data, thereby facilitating advancements in medical research and diagnostics.
In addition to its core imaging products, Tomocube provides a range of accessories designed to optimize the performance and versatility of its systems. These include HT-ready 96 well plates, TomoDish for accommodating both adherent and suspension cells, and the TomoChamber, a stage-top incubator tailored for long-term live cell imaging. The TomoPlate, an active vibration isolation system, ensures stable imaging environments, while vessel holders, environmental controllers, and 3D controllers further enhance the functionality and adaptability of Tomocube’s offerings.
Founded in 2015, Tomocube has rapidly evolved from a startup to a key innovator in the health care technology landscape. Its commitment to advancing optical imaging technology has not only solidified its position in the market but also contributed to significant progress in medical research and diagnostics. As the company continues to expand its product portfolio and explore new applications for its technology, Tomocube is well-positioned to maintain its leadership in the sector and drive future innovations in health care.
